Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 6/2016

03.08.2016 | Original Article

Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine

verfasst von: Natalia Gomez-Ospina, Anna I. Scott, Gia J. Oh, Donald Potter, Veena V. Goel, Lauren Destino, Nancy Baugh, Gregory M. Enns, Anna-Kaisa Niemi, Tina M. Cowan

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Hawkinsinuria is a rare disorder of tyrosine metabolism that can manifest with metabolic acidosis and growth arrest around the time of weaning off breast milk, typically followed by spontaneous resolution of symptoms around 1 year of age. The urinary metabolites hawkinsin, quinolacetic acid, and pyroglutamic acid can aid in identifying this condition, although their relationship to the clinical manifestations is not known. Herein we describe clinical and laboratory findings in two fraternal twins with hawkinsinuria who presented with failure to thrive and metabolic acidosis. Close clinical follow-up and laboratory testing revealed previously unrecognized hypoglycemia, hypophosphatemia, combined hyperlipidemia, and anemia, along with the characteristic urinary metabolites, including massive pyroglutamic aciduria. Treatment with N-acetyl-L-cysteine (NAC) restored normal growth and normalized or improved most biochemical parameters. The dramatic response to NAC therapy supports the idea that glutathione depletion plays a key role in the pathogenesis of hawkinsinuria.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (2014) N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 4:108–122CrossRefPubMedPubMedCentral Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (2014) N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 4:108–122CrossRefPubMedPubMedCentral
Zurück zum Zitat Blackford MG, Felter T, Gothard MD, Reed MD (2011) Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review. Clin Ther 33:1322–1330CrossRefPubMed Blackford MG, Felter T, Gothard MD, Reed MD (2011) Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review. Clin Ther 33:1322–1330CrossRefPubMed
Zurück zum Zitat Borden M, Holm J, Leslie J et al (1992) Hawkinsinuria in two families. Am J Med Genet 44:52–56CrossRefPubMed Borden M, Holm J, Leslie J et al (1992) Hawkinsinuria in two families. Am J Med Genet 44:52–56CrossRefPubMed
Zurück zum Zitat Brooker G, Jeffery J, Nataraj T, Sair M, Ayling R (2007) High anion gap metabolic acidosis secondary to pyroglutamic aciduria (5-oxoprolinuria): association with prescription drugs and malnutrition. Ann Clin Biochem 44:406–409CrossRefPubMed Brooker G, Jeffery J, Nataraj T, Sair M, Ayling R (2007) High anion gap metabolic acidosis secondary to pyroglutamic aciduria (5-oxoprolinuria): association with prescription drugs and malnutrition. Ann Clin Biochem 44:406–409CrossRefPubMed
Zurück zum Zitat Brownlee JM, Heinz B, Bates J, Moran GR (2010) Product analysis and inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to the treatment of Hawkinsinuria. Biochemistry 49:7218–7226CrossRefPubMed Brownlee JM, Heinz B, Bates J, Moran GR (2010) Product analysis and inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to the treatment of Hawkinsinuria. Biochemistry 49:7218–7226CrossRefPubMed
Zurück zum Zitat Danks DM, Tippett P, Rogers J (1975) A new form of prolonged transient tyrosinemia presenting with severe metabolic acidosis. Acta Paediatr Scand 64:209–214CrossRefPubMed Danks DM, Tippett P, Rogers J (1975) A new form of prolonged transient tyrosinemia presenting with severe metabolic acidosis. Acta Paediatr Scand 64:209–214CrossRefPubMed
Zurück zum Zitat Hocart CH, Halpern B, Hick LA, Wong CO (1983) Hawkinsinuria–identification of quinolacetic acid and pyroglutamic acid during an acidotic phase. J Chromatogr 275:237–243CrossRefPubMed Hocart CH, Halpern B, Hick LA, Wong CO (1983) Hawkinsinuria–identification of quinolacetic acid and pyroglutamic acid during an acidotic phase. J Chromatogr 275:237–243CrossRefPubMed
Zurück zum Zitat Item CB, Mihalek I, Lichtarge O et al (2007) Manifestation of hawkinsinuria in a patient compound heterozygous for hawkinsinuria and tyrosinemia III. Mol Genet Metab 91:379–383CrossRefPubMed Item CB, Mihalek I, Lichtarge O et al (2007) Manifestation of hawkinsinuria in a patient compound heterozygous for hawkinsinuria and tyrosinemia III. Mol Genet Metab 91:379–383CrossRefPubMed
Zurück zum Zitat Larsson A, Ristoff E, Anderson ME (2014) Glutathione synthetase deficiency and other disorders of the γ-Glutamyl cycle. In: Beaudet AL, Vogelstein B, Kinzler KW et al (eds) The online metabolic and molecular bases of inherited disease. The McGraw-Hill Companies, Inc., New York Larsson A, Ristoff E, Anderson ME (2014) Glutathione synthetase deficiency and other disorders of the γ-Glutamyl cycle. In: Beaudet AL, Vogelstein B, Kinzler KW et al (eds) The online metabolic and molecular bases of inherited disease. The McGraw-Hill Companies, Inc., New York
Zurück zum Zitat Lehnert W, Stogmann W, Engelke U, Wevers RA, van den Berg GB (1999) Long-term folluw-up of a new case of hawkinsinuria. Eur J Pediatr 158:578–582CrossRefPubMed Lehnert W, Stogmann W, Engelke U, Wevers RA, van den Berg GB (1999) Long-term folluw-up of a new case of hawkinsinuria. Eur J Pediatr 158:578–582CrossRefPubMed
Zurück zum Zitat Niederwieser A, Matasovic A, Tippett P, Danks DM (1977) A new sulfur amino acid, named hawkinsin, identified in a baby with transient tyrosinemia and her mother. Clin Chim Acta 76:345–356CrossRefPubMed Niederwieser A, Matasovic A, Tippett P, Danks DM (1977) A new sulfur amino acid, named hawkinsin, identified in a baby with transient tyrosinemia and her mother. Clin Chim Acta 76:345–356CrossRefPubMed
Zurück zum Zitat Niederwieser A, Matasovic A, Neuheiser F, Wetzel E (1978a) New tyrosine metabolites in humans: hawkinsin and cis- and trans-4-hydroxycyclohexylacetic acids. Unusual adsorption of deuterated and non-deuterated hawkinsin during gas chromatography. J Chromatogr 146:207–212CrossRefPubMed Niederwieser A, Matasovic A, Neuheiser F, Wetzel E (1978a) New tyrosine metabolites in humans: hawkinsin and cis- and trans-4-hydroxycyclohexylacetic acids. Unusual adsorption of deuterated and non-deuterated hawkinsin during gas chromatography. J Chromatogr 146:207–212CrossRefPubMed
Zurück zum Zitat Niederwieser A, Wadman SK, Danks DM (1978b) Excretion of cis- and trans-4-hydroxycyclohexylacetic acid in addition to hawkinsin in a family with a postulated defect of 4-hydroxyphenylpyruvate dioxygenase. Clin Chim Acta 90:195–200CrossRefPubMed Niederwieser A, Wadman SK, Danks DM (1978b) Excretion of cis- and trans-4-hydroxycyclohexylacetic acid in addition to hawkinsin in a family with a postulated defect of 4-hydroxyphenylpyruvate dioxygenase. Clin Chim Acta 90:195–200CrossRefPubMed
Zurück zum Zitat Ruetschi U, Cerone R, Perez-Cerda C et al (2000) Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet 106:654–662CrossRefPubMed Ruetschi U, Cerone R, Perez-Cerda C et al (2000) Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet 106:654–662CrossRefPubMed
Zurück zum Zitat Thodi G, Schulpis KH, Dotsikas Y et al (2016) Hawkinsinuria in two unrelated Greek newborns: identification of a novel variant, biochemical findings and treatment. J Pediatr Endocrinol Metabol JPEM 29:15–20 Thodi G, Schulpis KH, Dotsikas Y et al (2016) Hawkinsinuria in two unrelated Greek newborns: identification of a novel variant, biochemical findings and treatment. J Pediatr Endocrinol Metabol JPEM 29:15–20
Zurück zum Zitat Tomoeda K, Awata H, Matsuura T et al (2000) Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria. Mol Genet Metab 71:506–510CrossRefPubMed Tomoeda K, Awata H, Matsuura T et al (2000) Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria. Mol Genet Metab 71:506–510CrossRefPubMed
Zurück zum Zitat Wilcken B, Hammond JW, Howard N, Bohane T, Hocart C, Halpern B (1981) Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy. N Engl J Med 305:865–868CrossRefPubMed Wilcken B, Hammond JW, Howard N, Bohane T, Hocart C, Halpern B (1981) Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy. N Engl J Med 305:865–868CrossRefPubMed
Metadaten
Titel
Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine
verfasst von
Natalia Gomez-Ospina
Anna I. Scott
Gia J. Oh
Donald Potter
Veena V. Goel
Lauren Destino
Nancy Baugh
Gregory M. Enns
Anna-Kaisa Niemi
Tina M. Cowan
Publikationsdatum
03.08.2016
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 6/2016
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9963-8

Weitere Artikel der Ausgabe 6/2016

Journal of Inherited Metabolic Disease 6/2016 Zur Ausgabe

Highlights

News and views

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.